Posted by Michael Wonder on 25 Jan 2021
AstraZeneca is finding it hard to keep its COVID-19 vaccine promises
26 January 2021 - As countries scramble to inoculate their populations against COVID-19, the vaccine developed by AstraZeneca and the University of Oxford has been seen as a crucial element of that program.
That's not only because of its relative ease of deployment—unlike the vaccines from Pfizer/BioNTech and Moderna, it doesn't require extreme cooling—but also because of its low cost.
However, the events of recent days have cast doubt on AstraZeneca's ability to deliver what it's promised.
